KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.

Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson, Evan Braunstein, Vikas Gupta

Acta Haematol 149(3) 363-372

PMID40652928
PMCIDPMC12503453
DOI10.1159/000546585
发表日期2025-07-13
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1.:非 KM 图;Fig. 2.:非 KM 图;Fig. 3.:非 KM 图;Fig. 4.:森林图/亚组分析图。
摘要

摘要

UNLABELLED: <p>Introduction: Anemia can influence decisions regarding initiation, dosing, and discontinuation of Janus kinase inhibitor therapy for myelofibrosis. We evaluated the impact of new-onset or worsening anemia following ruxolitinib initiation on spleen response, symptom severity, and overall survival in patients with myelofibrosis. METHODS: This post hoc analysis used data from all patients enrolled in the phase 3b JUMP trial. Outcomes were stratified by presence or absence of new-onset or worsening anemia following ruxolitinib initiation, defined as hemoglobin decrease ≥15 g/L from baseline and hemoglobin <100 g/L (female)/<110 g/L (male) at Week 12, new transfusion requirement post-baseline until Week 12 (for baseline non-transfusion-dependent patients), or ≥50% increase from baseline in red blood cell transfusions through Week 12. RESULTS: Overall, 2,233 patients were included; 52.9% developed new-onset or worsening anemia up to Week 12. Ruxolitinib was associated with improvements in spleen length and myelofibrosis symptoms, regardless of the presence or absence of new-onset or worsening anemia or baseline anemia status. No differences in spleen response or overall survival were observed between patients with versus without new-onset or worsening anemia, regardless of baseline anemia status. CONCLUSIONS: These results support the use of ruxolitinib in patients with myelofibrosis, regardless of baseline anemia or development of treatment-related anemia. </p>.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Mean dose of ruxolitinib in patients with vs. without new-onset or worsening anemia. The 4 weeks’ average dose of ruxolitinib was assessed in the overall population ( a ), patients who were nonanemic at baseline ( b ), and patients who were anemic at baseline ( c ).
非 KM Figure
Fig. 2.Percentage of patients achieving ≥50% spleen length reduction from baseline at Weeks 24 and 48. Only patients with evaluable spleen response are included.
非 KM Figure
Fig. 3.Percentage of patients achieving ≥6.5-point increase in FACT-Lym TS at Weeks 24 and 48. Only patients with evaluable symptom response are included. FACT-Lym TS, Functional Assessment of Cancer Therapy–Lymphoma Total Score.
非 KM Figure
Fig. 4.OS of patients with vs. without new-onset or worsening anemia. OS was assessed separately for patients who were nonanemic ( a ) and anemic ( b ) at baseline. HR, hazard ratio; NE, not estimable; OS, overall survival.
非 KM Figure